{"id":"arq-151-cream-0-15-or-arq-151-cream-0-05","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL4303449","moleculeType":"Small molecule","molecularWeight":"552.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ARQ-151 activates the aryl hydrocarbon receptor, a nuclear receptor involved in immune homeostasis and barrier function. By engaging AhR in skin immune cells, it promotes anti-inflammatory pathways and enhances skin barrier integrity, making it suitable for inflammatory skin conditions. This mechanism allows localized immunomodulation without systemic immunosuppression.","oneSentence":"ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:27.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT04804605","phase":"PHASE3","title":"Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-25","conditions":"Atopic Dermatitis Eczema","enrollment":1220},{"nctId":"NCT04156191","phase":"PHASE1","title":"Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-23","conditions":"Atopic Dermatitis (Eczema)","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Roflumilast"],"phase":"phase_3","status":"active","brandName":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","genericName":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","companyName":"Arcutis Biotherapeutics, Inc.","companyId":"arcutis-biotherapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation. Used for Atopic dermatitis, Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}